Background: TRPML1 is reported to be involved in the pathogenesis of Alzheimer's disease (AD) by regulating autophagy; however, the underlying mechanism is not completely clear.
Introduction
Alzheimer's disease (AD) is the most common neurodegenerative disorder in the world and accounts for more than 60% of all cases of dementia. AD is characterized by severe cognitive impairments and progressive memory loss that affect the life and health of elderly people [1, 2] . The pathological characteristics of AD include the loss of pyramidal neurons, extracellular accumulation of senile plaques that contain amyloid-β (Aβ) deposits, and neurofibrillary tangles that contain hyper-phosphorylated tau [3, 4] . Autophagy is a highly conserved intracellular pathway involved in the organized elimination of proteins and organelles by lysosomes, and it is both required for cellular adaptation to nutrient deprivation and stress and important for neuronal survival [5] . Abnormalities in the lysosomal system have been identified in neurons of the AD brain, including a massive buildup of incompletely digested substrates within both dystrophic axons and dendrites and pathological endocytic pathway responses at the very earliest disease stage [6] . Moreover, autophagy not only exerts a degradative function but also mediates the secretion of Aβ, indicating a vital role for autophagy in the homeostasis of Aβ and placing it in a very unique and intriguing position in AD pathogenesis [7] . In particular, during autophagy, lysosomes fuse with autophagosomes to form autolysosomes. Following starvation-induced autophagy, nascent lysosomes are formed from autolysosomal membranes through an evolutionarily conserved cellular process called autophagic lysosome reformation (ALR) that is critical for maintaining lysosome homeostasis [8] . Since autophagy is strongly associated with AD pathogenesis and ALR is critical for maintaining lysosome homeostasis, it seems that ALR also participates in AD progression.
Transient receptor potential Mucolipin-1 (TRPML1) is widely expressed in mammalian cell lysosomes or in the endosome membrane [9] and is the main channel for lysosome Ca 2+ release and the key regulator for lysosomal storage and transportation [10] . In addition, TRPML1 also plays an important role in signal transduction and maintenance of lysosome acid homeostasis [11] . TRPML1 mutations can not only induce the occurrence of neurodegenerative lysosomal storage disorders but also affect the accumulation of autophagy. Thus, TRPML1 is considered to be the regulator of autophagy [9, 12] . Importantly, a recent study suggested that, in a triple transgenic gp120/APP/PS1 mouse, the HIV coat protein gp120 inhibits the activity of TRPML1 and thereby facilitates the intraneuronal accumulation of Aβ [13] . This finding raises the possibility that TRPML1 is involved in the pathogenesis of AD by regulating autophagy; however, the underlying mechanism is not clear completely.
Considering that the activation of peroxisome proliferator-activated receptor γ (PPARγ) has been reported to induce autophagy and that the AMP activated protein kinase/ mammalian target of rapamycin/p70ribosomal S6 Kinase (AMPK/mTOR/S6K) is the predominant signalling pathway that regulates autophagy [14] , we speculated that TRPML1 is involved in the pathogenesis of AD by regulating autophagy via the PPARγ/AMPK/mTOR signalling pathway. Our study was designed to test this hypothesis.
Materials and Methods
Animals APP/PS1 transgenic mice were purchased from the animal model centre of Nanjing University (Nanjing, China) and were maintained on a C57BL/6J background by crossing heterozygous transgenic mice with C57BL/6J breeders. Mice with TRPML1 overexpression were constructed as previously described [15] . The remaining mice were divided into 3 groups: one group received an intravenous injection of AMP inhibitor 8-bromo-AMP (8-bAMP) ( 
Aβ1-42 preparation and the isolation of primary neurons and cell culture
Aβ1-42 preparation was performed as previously described [16] . Mixed cortical and hippocampal neurons were isolated from embryos on embryonic day 14-16, as previously described [17] . Cells were maintained in Dulbecco's modified Eagle's medium (D-MEM; Nacalai tesque, Kyoto, Japan) containing 10% foetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin in a humidified atmosphere of 95% air and 5% CO 2 at 37˚C. Primary neuronal cultures were then treated with vehicle, 5uM Aβ1-42, or 5uM Aβ1-42 + propranolol for up to 72 hours in treatment. Recombinant adenovirus TRPML1 overexpression vector was constructed and infected into neurons as previously described [18] .
MTS assay
Cell viability was measured by the cellular ability to metabolize MTS (Promega Corporation, Madison, USA) in the presence of phenazine methosulfate to a formazan product, as described previously [17] . The results were expressed as a percentage of the absorbance at 490 nm of the control vehicle.
The Morris water maze (MWM) test
The MWM test was performed to evaluate the escape latency (the time to reach the hidden platform), travelled distance (the length of swim path) and time across the platform, as described in previous studies [19, 20] . Recognition tasks were performed as described previously [21] .
Calcium measurements Lysosomal Ca
2+ was measured using low-affinity rhodamine B dextran (10 kDa) in conjunction with Ca
2+
-insensitive Alexa Fluor 488 dextran (0.25 mg/mL; Invitrogen, Carlsbad, CA, USA), as described previously [22] .
Western blot analysis
Sample proteins were extracted and separated by SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Millipore, Germany). The blots were incubated with the primary antibodies anti-TRPML1, anti-PPARγ, anti-S6K, anti-p-S6K, anti-AMPK, anti-p-AMPK, antimTOR, anti-p-mTOR, anti-Beclin, anti-LC3, anti-LAMP-1 and anti-β-actin overnight at 4°C. The membranes were washed and then incubated with horseradish peroxidase-conjugated secondary antibodies (SigmaAldrich, St Louis, MO, USA) for 1 hour. The immunoreactive proteins were visualized with SuperSignal ECL (Pierce; Rockford, IL, USA), and the densities of the bands were analysed by ImageJ.
Statistical analyses
Data were presented as the mean ± standard error of the mean and analysed by using SPSS18.0. Comparisons among multiple groups were examined by 1-or 2-way analysis of variance followed by Fischer's protected least significant difference post hoc tests. Comparisons between two groups were analysed by Student's 2-tailed unpaired t-test. Significant differences were indicated by a p value < 0.05.
Results

TRPML1 was downregulated, the PPARγ/AMPK signalling pathway was activated, the mTOR/S6K signalling pathway was inhibited, and the ALR-related proteins were upregulated in APP/PS1 transgenic mice
The hippocampus was collected and used for Western blotting analysis. The results showed that the protein expression level of TRPML1 was downregulated in APP/PS1 transgenic mice compared with the control animals. Importantly, the protein expression level of PPARγ was upregulated in APP/PS1 transgenic mice compared with that in the controls (Fig. 1A) . The presence of the APP/PS1 transgenes in the mice also decreased the protein expression levels of p-S6K and p-mTOR and increased the expression of p-AMPK compared to that in the controls, indicating activation of the PPARγ/AMPK signalling pathway and inhibition of the mTOR/S6K signalling pathway (Fig. 1B) . Beclin, LC3 and LAMP-1 are markers of the autophagy-lysosomal system [23] . The protein expression levels of Beclin, LC3 and LAMP-1 were upregulated in mice with APP/PS1 transgenes compared with levels in the controls (Fig. 1C) . These results indicate the potential role of TRPML1 and the PPARγ/ AMPK/ mTOR signalling pathway in AD progression.
TRPML1 overexpression, PPARγ and AMPK inhibitors, and an mTOR activator reduced the expression levels of ALR-related proteins in APP/PS1 transgenic mice
To validate the potential role of TRPML1 and the PPARγ/AMPK/ mTOR signalling pathway in AD progression, TRPML1 was overexpressed in mice with the APP/PS1 transgenes, or the transgenic mice were treated with the AMP inhibitor 8-bAMP, the PPARγ antagonist GW9662 or the mTOR activator propranolol. We found that TRPML1 was significantly upregulated in the APP/PS1 model with TRPML1 overexpression compared with the APP/PS1 mice ( Fig.  2A) . We also observed that TRPML1 overexpression significantly increased the protein 
expression levels of p-S6K and p-mTOR in mice with the APP/PS1 transgenes in comparison with the APP/PS1 mice, which is comparable to the effects of the AMP inhibitor 8-bAMP, the PPARγ antagonist GW9662 and the mTOR activator propranolol (Fig. 2B) . We also found that TRPML1 overexpression significantly decreased the protein expression levels of Beclin, LC3 and LAMP-1 in mice with the APP/PS1 transgenes compared with the APP/PS1 mice. In addition, after treatment with the AMP inhibitor 8-bAMP, the PPARγ antagonist GW9662 or the mTOR activator propranolol in mice with the APP/PS1 transgenes, the protein expression levels of the ALR-related proteins Beclin, LC3 and LAMP-1 were also reduced (Fig. 2C ).
TRPML1 overexpression, PPARγ and AMPK inhibitors, and an mTOR activator rescued the memory and recognition impairments and neuronal apoptosis in mice with the APP/PS1 transgenes
We then found that the presence of APP/PS1 transgenes caused significant inductions in escape latency (Fig. 3A) , travel length (Fig. 3B) and time across the platform (Fig. 3C) (Fig.  3D) . TRPML1 overexpression or treatment with 8-bAMP, GW9662, or propranolol caused significant reductions in escape latency (Fig. 3A) , travel length (Fig. 3B) , and time across the platform (Fig. 3C ) and markedly improved the recognition index (Fig. 3D ) in APP/ PS1 transgenic mice compared to mice without treatment. TUNEL staining was used to detect neuronal apoptosis in AD mice. As shown in Fig. 3E and 3F, the presence of APP/ Cellular Physiology and Biochemistry
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PS1 transgenes caused a significant increase in the neuronal apoptotic rate compared with that in the controls. Importantly, a marked reduction in the neuronal apoptotic rate in the APP/PS1 transgenic mice was found with TRPML1 overexpression or with 8-bAMP, GW9662 or propranolol treatment. These investigations suggested that TRPML1 overexpression or inhibitors of the PPARγ/AMPK signalling pathway prevented the dysfunctions of spatial memory and recognition, as well as neuronal apoptosis.
TRPML1 overexpression or the mTOR activator propranolol attenuated the Aβ1-42-suppressed cell viability and the Aβ1-42-decreased lysosomal [Ca 2+ ] ion concentration in vitro
Next, primary neurons were isolated from the hippocampus and treated with Aβ1-42 in vitro. Our results showed that cell viability was significantly inhibited in Aβ1-42-treated neurons compared with the controls. In contrast, TRPML1 overexpression or treatment with the mTOR activator propranolol markedly attenuated the Aβ1-42-suppressed cell viability of neurons in vitro (Fig. 4A) . Furthermore, Aβ1-42 treatment caused a significant decrease in the lysosomal [Ca 2+ ] ion concentration compared with the control, and TRPML1 overexpression or treatment with the mTOR activator propranolol significantly attenuated the Aβ1-42-mediated decrease in lysosomal [Ca 2+ ] ion concentration (Fig. 4B) .
TRPML1 overexpression or the mTOR activator propranolol attenuated the Aβ1-42-inhibited mTOR/S6K signalling pathway and the Aβ1-42-induced ALR-related protein expression levels in vitro
As shown in Fig. 5 , our results showed that the protein expression levels of p-S6K and p-mTOR were inhibited in neurons with Aβ1-42-treatment compared with the controls. Inversely, TRPML1 overexpression or the mTOR activator propranolol markedly attenuated the Aβ1-42-inhibited mTOR/S6K signalling pathway, inducing the protein expression of p-S6K and p-mTOR. In addition, Aβ1-42 treatment caused increased expression levels of the ALR-related proteins Beclin, LC3 and LAMP-1 compared with the controls, and TRPML1 overexpression or the mTOR activator propranolol significantly attenuated the Aβ1-42-induced ALR-related protein expression levels. 
Discussion
The mucolipin subfamily of TRP proteins (TRPMLs) contain six transmembranespanning proteins that consist of cytosolic N-and C-termini. There are three TRPML proteins, TRPML1 (also called MCOLN1), TRPML 2 (also called MCOLN2) and TRPML 3 (also called MCOLN3), in mammals [9] . Loss-of-function mutations in the human TRPML1 gene cause type IV mucolipidosis (ML4), a devastating neurodegenerative disease that causes retinal degeneration and mental retardation [9, 24] . Additionally, TRPML1-/-cells from ML4 patients are characterized by the accumulation of enlarged endosomal/ lysosomal compartments (vacuoles) in which lipids and other biomaterials accumulate, suggesting defective lysosomal biogenesis and trafficking [9, 25] . In addition, a previous study suggested that a TRPML1 agonist facilitates the lysosomal clearance of proteins and lipids in a mouse model of gp120-facilitated amyloid deposition [26] . To some extent, these investigations showed the potential role of TRPML1 in AD progression. Indeed, we found that TRPML1 was downregulated in APP/PS1 transgenic mice, and TRPML1 overexpression reduced the expression levels of ALR-related proteins, rescued both memory and recognition impairments and attenuated neuronal apoptosis in mice with APP/PS1 transgenes in vivo. In addition, TRPML1 overexpression attenuated Aβ1-42-suppressed cell viability, Aβ1-42- ] ion concentration, and Aβ1-42-induced ALR-related protein expression levels in vitro.
A previous study indicated that the PPARγ agonist troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells [27] . However, rosiglitazone, a selective PPAR-γ-inhibitor, is reported to induce autophagy in H295R cells and cell cycle deregulation in SW13 adrenocortical cancer cells [28] . It seems that the role of PPARγ in autophagy remains unclear. PPARγ agonists are considered new therapeutic agents for the treatment of AD [29] . These protective effects are primarily considered to result from the anti-inflammatory and anti-oxidant actions of PPARγ [30] . Moreover, other studies showed that autophagy is not only affected by AMPK, a key energy sensor that regulates cellular metabolism to maintain energy homeostasis, but also affected by mTOR, a central cell-growth regulator that integrates growth factors and nutrient signals [31, 32] . Autophagy is promoted by AMPK, and the mTOR/S6K signalling pathway is well known to negatively regulate autophagy [31, 33] . A previous study indicated that increased mTOR activity attenuates autophagy and generates proto-lysosomal tubules and vesicles, which extrude from autolysosomes and ultimately mature into functional lysosomes that restore the full complement of lysosomes to the cell, revealing its vital role in ALR [34] . Moreover, Li et al. revealed that the induction of autophagy by telmisartan occurred with a dose-dependent increase in the expression of PPARγ and p-AMPK and a decrease in the expression of p-mTOR, whereas GW9662 attenuated these expression levels [14] . Similarly, we found that the presence of the APP/PS1 transgenes in mice increased the protein expression level of p-AMPK but decreased the expression levels of p-S6K and p-mTOR. The AMP inhibitor 8-bAMP, the PPARγ antagonist GW9662 and the mTOR activator propranolol reduced the expression levels of ALR-related proteins, rescued the memory and recognition impairments and attenuated neuronal apoptosis in mice with the APP/PS1 transgenes in vivo. In addition, propranolol attenuated Aβ1-42-suppressed cell viability, Aβ1-42-decreased lysosomal [Ca 2+ ] ion concentration, and Aβ1-42-induced ALRrelated protein expression levels in vitro.
Importantly, TRPML1 overexpression reduced the protein expression level of p-AMPK and induced the protein expression levels of p-S6K and p-mTOR in mice with the APP/ PS1 transgenes in comparison with the controls. TRPML1 overexpression also induced protein expression levels of p-S6K and p-mTOR in the Aβ1-42-treated cells compared with the controls. The effects of 8-bAMP, GW9662 or propranolol on rescuing the memory and recognition impairments and attenuating neuronal apoptosis, as well as the effects of propranolol on reversing Aβ1-42-suppressed cell viability, Aβ1-42-decreased lysosomal [Ca 2+ ] ion concentration and Aβ1-42-induced ALR-related protein expression levels, were comparable to the effects of TRPML1 overexpression. Thus, it seems that TRPML1 is involved in the pathogenesis of AD at least partially through the regulation of autophagy via the PPARγ/AMPK/mTOR signalling pathway.
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